IP Library › Granted Patent US 12673063
Granted Patent B2
US 12673063 · App. 17/920,502 · Granted Jul 7, 2026

Methods and materials for treatment of fibrosis

Inventors: Joseph F. Arboleda-Velasquez (Newton, MA); Leo A. Kim (Boston, MA)
Assignee: The Schepens Eye Research Institute, Inc.
A61K31/5513A61K31/4439A61K31/7088A61P11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673063
App. No.
17/920,502
Granted
Jul 7, 2026
Kind
B2
Abstract

Described herein are methods for treating and reducing risk of fibrosis, e.g., pulmonary fibrosis, in a subject by administering an inhibitor of RUNX family transcription factor 1 (RUNX1) or core-binding factor subunit beta (CBFβ), e.g., in a subject who has a viral infection.

Claims (4)

1 . A method for treating pulmonary fibrosis in a subject, the method comprising administering an effective amount of an inhibitor of runt-related family transcription factor 1 (RUNX1) selected from Ro24-7429 (7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine); Ro5-3335 (7-Chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-2H-1,4-benzodiazepin-2-one); 7-fluoro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-Benzodiazepin-2-amine; 7-fluoro-1,3-dihydro-5-(1H-pyrrol-2yl)-2H-1,4-benzodiazepin-2-one; NSC140873; MLS000548294; MLS001048862; or NSC156594.

2 . The method of claim 1 , wherein the subject has a viral, bacterial, or fungal infection, or has had a chemical lung injury.

3 . A method for treating pulmonary fibrosis in a subject who has a coronavirus infection, the method comprising administering an effective amount of an inhibitor of runt-related family transcription factor 1 (RUNX1) selected from Ro24-7429 (7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine); Ro5-3335 (7-Chloro-1,3-dihydro-5-(1H-pyrrol-2-yl)-2H-1,4-benzodiazepin-2-one); 7-fluoro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-Benzodiazepin-2-amine; 7-fluoro-1,3-dihydro-5-(1H-pyrrol-2yl)-2H-1,4-benzodiazepin-2-one; NSC140873; MLS000548294; MLS001048862; or NSC156594.

4 . The method of claim 3 , wherein the coronavirus infection is infection with SARS or SARS-CoV-2.